Clinical Trial Update: Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer

View source ↗

Summary

A clinical trial investigating adherence to aromatase inhibitors with or without abemaciclib in early-stage HER2-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• Anastrozole (Anastrozole)
• Exemestane (Exemestane)
• Letrozole (letrozole)

Snippet

Sponsor: Institute of Oncology Ljubljana | Conditions: Early Breast Cancer, Hormone Receptor Positive Tumor | Status: RECRUITING